Fresenius Kabi Recalls Tyenne Injection Vials Due to Glass Particle Contamination

Fresenius Kabi has issued a nationwide recall for one lot of its Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL vials. The recall is due to the presence of glass particles, which could cause local irritation, pain, swelling, or vein inflammation if administered. This action aims to prevent potential adverse health consequences for patients.